

Bioloogiliste ravimite arendus Icosagenis ja keemikute roll selles tegevuses.

Mart Ustav Icosagen Grupi juhataja

DOB 16.07.1949

Curriculum vitae Mart Ustav, Sen.

- 1. Education Organic and Bioorganic Chemistry, 1972, Univ. Of Tartu
- 2. First job: Institute of Cybernetics, Tallinn researcher, enzyme kinetics 1974
- 3. Ph.D. rRNA-protein interactions, Univ. of Tartu, 1976-1979
- 4. Post-doctoral Fellow Uppsala University 1982-1985
- 5. Head of Laboratory of Oncogenesis, EBC 1985-2001
- 6. Visiting scientist Cold Spring Harbour Laboratory, Long Island, NY, USA (1989-1992)
- 7. Professor of Microbiology and Virology 1992-2007, Univ. of Tartu
- 8. Director of the Institute of Molecular and Cell Biology 1996-1999
- 9. Howard Hughes Medical Institute Fellow, USA 1995-2005
- **10. Member of the Academy of Sciences of Estonia 2001**
- 11. Professor of Biomedical Technology 2007-2021. Since 2021 Professor Emeritus TUIT.
- 12. Director of the Institute of Technology, University of Tartu, 2002-2007, 2012-2017
- 13. Founder and CSO FIT Biotech Eesti AS 2001-2011; Chairman of the Board Quattromed AS 1999 -2008)
- 14. Founder and CEO, Icosagen Group (Icosagen AS, Icosagen Cell Factory OÜ, Ico Park OÜ, Icosagen Technology Inc.) Since 2008...nfidential


The first 10-years of Icosagen as CAGEN Quattromed

- Quattromed was founded as a molecular diagnostic company for providing services to Estonian medical institutions. 2001 FIT Biotech Oy acquired 22.3% of the Quattromed shares and established FIT Biotech Oy Eesti filiaal
 - Diversification of medical services and establishment of Quattromed Cell Factory as a subsidiary company

2008

- A leading medical diagnostics and biotechnology group in Estonia, 80 FTE; service labs in several cities; revenue EUR 4.5 MEUR
- Activities:
- medical diagnostics: molecular diagnostics, clinical chemistry, hematology, cytology, immunology etc
- molecular- and cell biology products and services
- immunoanalysis products and services for detection of allergic causativ proteins in rubber products
- Q3: the medical diagnostic subsidiary along the trademark Quattromed was sold to private equity firm. Restructuring of the group and business model.
- Establishment of Icosagen Group inn 2009


Biologic drugs are high molecular weight complex molecules



Mellstedt H. Clinical considerations for biosimilar antibodies. EJC Suppl. 2013 Dec;11(3):1-11. doi: 10.1016/S1359-6349(13)70001-6. PMID: 26217160; PMCID: PMC4048039.



Antibody drugs are highest selling drugs



Lu, RM., Hwang, YC., Liu, IJ. *et al.* Development of therapeutic antibodies for the treatment of diseases. *J Biomed Sci* **27**, 1 (2020). https://doi.org/10.1186/s12929-019-0592-z

Biologic drugs are highest selling drugs

Oncology

Immune-mediated disorders

Cardiovascular / hemostasis


Infectious diseases

Genetic diseases

Neurological disorders

Ophthalmic disorders

Musculoskeletal disorders



Total=131


Top-10 selling drugs in 2021


Drug's name	Manufacturer	Estimated sales in B\$ (2021)	Drug type
Humira	AbbVie	20	Antibody
Keytruda	Merck & Co	17	Antibody
Spikevax	Moderna	15	Vaccine
Revlimid	BMS	13	Small molecule
Eliquis	BMS/Pfizer	11	Small molecule
Imbruvica	J&J/AbbVie	10	Small molecule
			Recombinant
Eylea	Regeneron/Bayer	9	fusion protein
Stelara	1 % 1	9	Antibody
Biktarvy	Gilead	8	Small molecule


NASDAQ

Therapeutic antibodies are produced using Chinese Hamster Ovary (CHO) cells <u>as cell factories</u>.

>100 billion EUR worth of biologic drugs are produced in CHO cells annually









Icosagen Group

- Discovers, develops and manufactures mammalian protein drug candidates
- From R&D concepts to clinical development stages
- 180+ FTEs (38 PhD)
- ISO 9001:2015, ISO 17025
- >25 patents in 7 families (EU, US, CA, JP, AU)
- 6200m² lab & office space, 300m² animal facility
- 50L, 200L, 1000L single-use GMP bioreactors

IC SAGEN

Tartu ESTONIA

Organogram of Icosagen Group

Icosagen AS

Management, financing, QC/QA, Sales&Marketing Catalogue products/Services: catalog products (antibodies, proteins, ELISA kits); food safety/quality control services.

Icosagen Cell Factory

R&D, Business Development protein production, antibody discovery, CHO cell line development services; technology licensing


Icosagen Technologies

Established in 2015. US Customer Relations and Sales


IcoPark

Established in 2013. Development the infrasturcture of Icosagen Group





The CRDMO Approach – From R&D and Pre-Clinical to Clinical Stages




In 2022, we were trusted by many partners







Multispecific antibodies aka Frankenbodies? We (will) have them all produced!*




Icosagen Core Competencies and Services






Innovation value generation arcs




IC SAGEN

Innovation projects




Icosagen's vision – organic growth strategy





In-house therapeutic developments





PLOS PATHOGENS

🔓 OPEN ACCESS 🝺 PEER-REVIEWED

RESEARCH ARTICLE

Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates


Paule Hermet, Benoît Delache, Cecile Herate, Esther Wolf, Gaily Kivi, Erkki Juronen, Karl Mumm, Eva Žusinaite, Denis Kainov, Eve Sankovski, Kai Virumäe, Anu Planken, Andres Merits, Jessica E. Besaw, Ai Woon Yee, Takefumi Morizumi, Kyumhyuk Kim, Anling Kuo, Asma Berriche, Nathalie Dereuddre-Bosquet, Quentin Sconosciuti, Thibaut Naninck, Francis Relouzat, Mariangela Cavarelli, Mart Ustav, Derek Wilson, Oliver P. Ernst, Andres Männik, Roger LeGrand, Mart Ustav Jr. 🖾 [view less]


Published: August 2, 2023 • https://doi.org/10.1371/journal.ppat.1011532



21


Schematic representation of the antibody nebulization system and pharmacology study protocol








Antibody ICO-hu104 reduces viral load in non-human primates through nebulization and intravenous administration



SLC2A1 (GLUT1) – overexpressed in several cancers, predicts poor survival




DESIGN OBJECTIVE

Highly specific inhibitor of GLUT1

- GLUT1 12TM glucose transporter
- Overexpressed in multiple cancers
- Small molecule inhibitors have shown preclinical efficacy
- Small therapeutic window on target toxicity effects (seizures, mobility impairment, body temperature loss)

Evaluate effects as combination therapy with approved or clinically evaluated small molecule drugs Confirm increased therapeutic window – non or limited toxicity effects in vivo

GLUT-1 is overexpressed in cancer and high expression predicts poor survival





Pancreatic ductal adenocarcinoma

Liver hepatocellular carcinoma

Deng et. al 2014, Nature


EC






Kaplan-Meier Plotter

Anti-SLC2A1 and OXPHOS Inhibitor Synergistic Tumor Growth Inhibition in vivo



Significance is shown for Phenformin vs #33 + Phenformin

In-house diagnostic developments





Our mission is to establish a world-class drug development and production company in Estonia and provide employment for highly qualified individuals in Estonia.

Driving force: un-met medical needs in therapeutics and diagnostics

Development of antibody based therapeutic candidates

Providing world-class services in the development and manufacturing of biotherapeutics

Scientific excellence

Novel technologies to support product and service development Highly professional and qualified team





Research partners





Many thanks to our young and ambitious team members at Icosagen who are very creative and hard-working! They will make a difference and would change the World!

Also, thank you for listening!